Mentor Capital, Inc. Provides Public Market (MNTR) Funding For Cancer
Immunology Leader Quantum Immunologics
Mentor Capital, Inc. (MNTR) and Quantum Immunologics, Inc. bring together $145 Million in public financing authorization
with leading edge breast cancer immunotherapy now in FDA trials.
Instead of enduring mastectomies, chemotherapy and
radiation, patients receiving Quantum's patented Oncofetal Antigen (OFA) dendritic cell therapy
process, like with any dendritic cell immunotherapy process, are expected to experience only flu-like
symptoms that naturally follow any immune system activation.
OFA has been found on all 500 cancers tested and is not found on
healthy tissue.
|